Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections.
Atevirdine is a nonnucleoside reverse transcriptase inhibitor with in vitro activity against human immunodeficiency virus type 1 and is currently in phase II clinical trials. Atevirdine is most soluble at a pH of < 2, and therefore, normal gastric acidity is most likely necessary for optimal bioavai...
Salvato in:
| Pubblicato in: | Antimicrob Agents Chemother |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Society for Microbiology (ASM)
1996
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC163195/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8851608/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.40.3.767 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
